Suicide in schizophrenia

Expert Review of Neurotherapeutics

Volumn 10, Issue 7, 2010, Pages 1153-1164

  Carlborg, Andreas ^a   Winnerbäck, Kajsa ^a   Jönsson, Erik G ^a   Jokinen, Jussi ^a   Nordstrm, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

attempted suicide; risk factor; schizophrenia; suicidal behavior; suicide; suicide risk; treatment

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; HOMOVANILLIC ACID; LITHIUM; PHOSPHOPROTEIN DARPP 32; SEROTONIN; SEROTONIN TRANSPORTER; SEROTONIN TRANSPORTER 2A; TRYPTOPHAN HYDROXYLASE; TRYPTOPHAN HYDROXYLASE 1; UNCLASSIFIED DRUG;

BIPOLAR DISORDER; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; GENETIC ASSOCIATION; HOPELESSNESS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; INTELLIGENCE QUOTIENT; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL PSYCHOLOGY; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; PSYCHOLOGY;

HUMANS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SUICIDE;

EID: 77954203381     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.82     Document Type: Review

References (149)

1. MacDonald AW, Schulz SC. What we know: fndings that every theory of schizophrenia should explain. Schizophr. Bull. 35, 493-508 (2009).
2. Dalman C, Thomas HV, David AS, Gentz J, Lewis G, Allebeck P. Signs of asphyxia at birth and risk of schizophrenia. Population-based case-control study. Br. J. Psychiatry 179, 403-408 (2001).
3. Ichiki M, Kunugi H, Takei N et al. Intra-uterine physical growth in schizophrenia: evidence confrming excess of premature birth. Psychol. Med. 30, 597-604 (2000).
4. Dalman C, Allebeck P. Paternal age and schizophrenia: further support for an association. Am. J. Psychiatry 159, 1591-1592 (2002).
5. Bradbury TN, Miller GA. Season of birth in schizophrenia: a review of evidence, methodology, and etiology. Psychol. Bull. 98, 569-594 (1985).
6. Barr CE, Mednick SA, Munk-Jorgensen P. Exposure to infuenza epidemics during gestation and adult schizophrenia. A 40-year study. Arch. Gen. Psychiatry 47, 869-874 (1990).
7. Dalman C, Allebeck P, Gunnell D et al. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am. J. Psychiatry 165, 59-65 (2008).
8. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the infuence of sex, urbanicity, migrant status and methodology. BMC Med. 2, 13 (2004).
9. Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. Int. Rev. Psychiatry 21, 152-162 (2009).
10. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality Epidemiol. Rev. 30, 67-76 (2008).
11. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch. Gen. Psychiatry 60, 565-571 (2003).
12. McGrath JJ. Variations in the incidence of schizophrenia: data versus dogma. Schizophr. Bull. 32, 195-197 (2006).
13. American Psychiatric Association (APA). Practice guideline for the assessment and treatment of patients with suicidal behaviors. Am. J. Psychiatry 1-60 (2003).
14. Hawton K, van Heeringen K. Suicide. Lancet 373, 1372-1381 (2009).
15. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 28(Suppl. 2), 17-54 (2003).
16. Bleuler E. Dementia Praecox or the Group Schizophrenias. International University Press, NY, USA (1950).
17. Baxter D, Appleby L. Case register study of suicide risk in mental disorders. Br. J. Psychiatry 175, 322-326 (1999).
18. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr. Bull. 16, 571-589 (1990).
19. Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br. J. Psychiatry 172, 35-37 (1998).
20. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch. Gen. Psychiatry 62, 247-253 (2005).
21. Ösby U, Correia N, Brandt L, Ekbom A, Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 45, 21-28 (2000).
22. Nordentoft M, Laursen TM, Agerbo E, Qin P, Hoyer EH, Mortensen PB. Change in suicide rates for patients with schizophrenia in Denmark, 1981-1997: nested case-control study. Br. Med. J. 329, 261 (2004).
23. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry 64, 1123-1131 (2007).
24. Mortensen PB, Juel K. Mortality and causes of death in frst admitted schizophrenic patients. Br. J. Psychiatry 163, 183-189 (1993).
25. Allebeck P, Varla A, Wistedt B. Suicide and violent death among patients with schizophrenia. Acta Psychiatr. Scand. 74, 43-49 (1986).
26. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br. J. Psychiatry 171, 502-508 (1997).
27. Mann JJ, Waternaux C, Haas GL, Malone KM. Toward a clinical model of suicidal behavior in psychiatric patients. Am. J. Psychiatry 156, 181-189 (1999).
28. Turecki G. Dissecting the suicide phenotype: the role of impulsive-aggressive behaviours. J. Psychiatry Neurosci. 30, 398-408 (2005).
29. Mann JJ. Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 4, 819-828 (2003).
30. Preston E, Hansen L. A systematic review of suicide rating scales in schizophrenia. Crisis 26, 170-180 (2005).
31. Radomsky ED, Haas GL, Mann JJ, Sweeney JA. Suicidal behavior in patients with schizophrenia and other psychotic disorders. Am. J. Psychiatry 156, 1590-1595 (1999).
32. Kuo CJ, Tsai SY, Lo CH, Wang YP, Chen CC. Risk factors for completed suicide in schizophrenia. J. Clin. Psychiatry 66, 579-585 (2005).
33. Alaräisänen A, Miettunen J, Rasanen P, Fenton W, Koivumaa-Honkanen HT, Isohanni M. Suicide rate in schizophrenia in the Northern Finland 1966 Birth Cohort. Soc. Psychiatry Psychiatr. Epidemiol. 44, 1107-1110 (2009).
34. Hawton K, Sutton L, Haw C, Sinclair J, Deeks JJ. Schizophrenia and suicide: systematic review of risk factors. Br. J. Psychiatry 187, 9-20 (2005). (Pubitemid 41002508)
35. Reutfors J, Brandt L, Jönsson EG, Ekbom A, Sparen P, Ösby U. Risk factors for suicide in schizophrenia: fndings from a Swedish population-based case-control study. Schizophr. Res. 108, 231-237 (2009).
36. Carlborg A, Jokinen J, Jönsson EG, Nordström AL, Nordström P. Long-term suicide risk in schizophrenia spectrum psychoses: survival analysis by gender. Arch. Suicide Res. 12, 347-351 (2008).
37. Heilä H, Isometsä ET, Henriksson MM, Heikkinen ME, Marttunen MJ, Lönnqvist JK. Suicide and schizophrenia: a nationwide psychological autopsy study on age-and sex-specifc clinical characteristics of 92 suicide victims with schizophrenia. Am. J. Psychiatry 154, 1235-1242 (1997).
38. Qin P, Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch. Gen. Psychiatry 62, 427-432 (2005).
39. Ho TP. The suicide risk of discharged psychiatric patients. J. Clin. Psychiatry 64, 702-707 (2003).
40. Reutfors J, Brandt L, Ekbom A, Isacsson G, Sparen P, Ösby U. Suicide and hospitalization for mental disorders in Sweden: a population-based case-control study. J. Psychiatr. Res. DOI:10.1016/j.jpsychires.2010.02.003 (2010) (Epub ahead of print).
41. Roy A. Suicide in chronic schizophrenia. Br. J. Psychiatry 141, 171-177 (1982).
42. Yarden PE. Observations on suicide in chronic schizophrenics. Compr. Psychiatry 15, 325-333 (1974).
43. Lee HC, Lin HC. Are psychiatrist characteristics associated with postdischarge suicide of schizophrenia patients? Schizophr. Bull. 35, 760-765 (2009).
44. Hansen V, Jacobsen BK, Arnesen E. Cause-specifc mortality in psychiatric patients after deinstitutionalisation. Br. J. Psychiatry 179, 438-443 (2001).
45. Seeman MV. An outcome measure in schizophrenia: mortality. Can. J. Psychiatry 52, 55-60 (2007).
46. Pompili M, Amador XF, Girardi P et al. Suicide risk in schizophrenia: learning from the past to change the future. Ann. Gen. Psychiatry 6, 10 (2007).
47. Cavanagh JT, Carson AJ, Sharpe M, Lawrie SM. Psychological autopsy studies of suicide: a systematic review. Psychol. Med. 33, 395-405 (2003).
48. Carlborg A, Jokinen J, Nordström AL, Jönsson EG, Nordström P. Attempted suicide predicts suicide risk in schizophrenia spectrum psychosis. Nord. J. Psychiatry 64, 68-72 (2009).
49. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br. J. Psychiatry 170, 205-228 (1997).
50. Tidemalm D, Langström N, Lichtenstein P, Runeson B. Risk of suicide after suicide attempt according to coexisting psychiatric disorder: Swedish cohort study with long term follow-up. Br. Med. J. 337, a2205 (2008).
51. Harkavy-Friedman JM, Restifo K, Malaspina D et al. Suicidal behavior in schizophrenia: characteristics of individuals who had and had not attempted suicide. Am. J. Psychiatry 156, 1276-1278 (1999).
52. Hunt IM, Kapur N, Windfuhr K et al. Suicide in schizophrenia: fndings from a national clinical survey. J. Psychiatr. Pract. 12, 139-147 (2006).
53. Gupta S, Black DW, Arndt S, Hubbard WC, Andreasen NC. Factors associated with suicide attempts among patients with schizophrenia. Psychiatric Services 49, 1353-1355 (1998).
54. Roy A, Mazonson A, Pickar D. Attempted suicide in chronic schizophrenia. Br. J. Psychiatry 144, 303-306 (1984).
55. Haw C, Hawton K, Sutton L, Sinclair J, Deeks J. Schizophrenia and deliberate self-harm: a systematic review of risk factors. Suicide Life Threat. Behav. 35, 50-62 (2005). (Pubitemid 40381441)
56. Drake RE, Gates C, Cotton PG. Suicide among schizophrenics: a comparison of attempters and completed suicides. Br. J. Psychiatry 149, 784-787 (1986).
57. Harkavy-Friedman JM, Nelson EA, Venarde DF, Mann JJ. Suicidal behavior in schizophrenia and schizoaffective disorder: examining the role of depression. Suicide Life Threat. Behav. 34, 66-76 (2004).
58. Jones JS, Stein DJ, Stanley B, Guido JR, Winchel R, Stanley M. Negative and depressive symptoms in suicidal schizophrenics. Acta Psychiatr. Scand. 89, 81-87 (1994).
59. Nordentoft M, Jeppesen P, Abel M et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with frst-episode psychosis. One-year follow-up of a randomised controlled trial. Br. J. Psychiatry Suppl. 43, S98-S106 (2002).
60. Limosin F, Loze JY, Philippe A, Casadebaig F, Rouillon F. Ten-year prospective follow-up study of the mortality by suicide in schizophrenic patients. Schizophr. Res. 94, 23-28 (2007).
61. Gut-Fayand A, Dervaux A, Olie JP, Loo H, Poirier MF, Krebs MO. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Res. 102, 65-72 (2001).
62. Barbee JG, Clark PD, Crapanzano MS, Heintz GC, Kehoe CE. Alcohol and substance abuse among schizophrenic patients presenting to an emergency psychiatric service. J. Nerv. Ment. Dis. 177, 400-407 (1989).
63. Mauri MC, Volonteri LS, De Gaspari IF, Colasanti A, Brambilla MA, Cerruti L. Substance abuse in frst-episode schizophrenic patients: a retrospective study. Clin. Pract. Epidemol. Ment. Health 2, 4 (2006).
64. Compton MT, Kelley ME, Ramsay CE et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in frst-episode patients. Am. J. Psychiatry 166, 1251-1257 (2009).
65. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br. Med. J. 325, 1199 (2002).
66. Miller R, Ream G, McCormack J, Gunduz-Bruce H, Sevy S, Robinson D. A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in frst-episode schizophrenia. Schizophr. Res. 113, 138-144 (2009).
67. Cantwell R. Substance use and schizophrenia: effects on symptoms, social functioning and service use. Br. J. Psychiatry 182, 324-329 (2003).
68. Zisook S, Heaton R, Moranville J, Kuck J, Jernigan T, Braff D. Past substance abuse and clinical course of schizophrenia. Am. J. Psychiatry 149, 552-553 (1992).
69. Caton CL, Shrout PE, Eagle PF, Opler LA, Felix A, Dominguez B. Risk factors for homelessness among schizophrenic men: a case-control study. Am. J. Public Health 84, 265-270 (1994).
70. Drake RE, Wallach MA, Teague GB, Freeman DH, Paskus TS, Clark TA. Housing instability and homelessness among rural schizophrenic patients. Am. J. Psychiatry 148, 330-336 (1991).
71. Menezes PR, Johnson S, Thornicroft G et al. Drug and alcohol problems among individuals with severe mental illness in south London. Br. J. Psychiatry 168, 612-619 (1996).
72. Duke PJ, Pantelis C, Barnes TR. South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br. J. Psychiatry 164, 630-636 (1994).
73. Scott H, Johnson S, Menezes P et al. Substance misuse and risk of aggression and offending among the severely mentally ill. Br. J. Psychiatry 172, 345-350 (1998).
74. Fazel S, Grann M, Carlström E, Lichtenstein P, Långström N. Risk factors for violent crime in Schizophrenia: a national cohort study of 13,806 patients. J. Clin. Psychiatry 70, 362-369 (2009).
75. Fazel S, Långström N, Hjern A, Grann M, Lichtenstein P. Schizophrenia, substance abuse, and violent crime. JAMA 301, 2016-2023 (2009).
76. Fenton WS. Depression, suicide, and suicide prevention in schizophrenia. Suicide Life Threat. Behav. 30, 34-49 (2000).
77. De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr. Res. 47, 127-134 (2001).
78. Drake RE, Gates C, Cotton PG, Whitaker A. Suicide among schizophrenics. Who is at risk? J. Nerv. Ment. Dis. 172, 613-617 (1984).
79. Alaräisänen A, Miettunen J, Lauronen E, Rasanen P, Isohanni M. Good school performance is a risk factor of suicide in psychoses: a 35-year follow up of the Northern Finland 1966 Birth Cohort. Acta Psychiatr. Scand. 114, 357-362 (2006).
80. Montross LP, Zisook S, Kasckow J. Suicide among patients with schizophrenia: a consideration of risk and protective factors. Ann. Clin. Psychiatry 17, 173-182 (2005).
81. Bourgeois M, Swendsen J, Young F et al. Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am. J. Psychiatry 161, 1494-1496 (2004).
82. Kim CH, Jayathilake K, Meltzer HY. Hopelessness, neurocognitive function, and insight in schizophrenia: relationship to suicidal behavior. Schizophr. Res. 60, 71-80 (2003).
83. Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J. Clin. Psychiatry 67(Suppl. 5), 3-8 (2006).
84. Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 176(2-3), 109-113 (2010).
85. Haukka J, Tiihonen J, Härkänen T, Lönnqvist J. Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia. Pharmacoepidemiol. Drug Saf. 17, 686-696 (2008).
86. Pompili M, Lester D, Innamorati M, Tatarelli R, Girardi P. Assessment and treatment of suicide risk in schizophrenia. Expert Rev. Neurother. 8, 51-74 (2008).
87. Taiminen TJ, Kujari H. Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. A controlled retrospective study. Acta Psychiatr. Scand. 90, 247-251 (1994).
88. Lester D. Sex differences in completed suicide by schizophrenic patients: a meta-analysis. Suicide Life Threat. Behav. 36, 50-56 (2006).
89. Canetto SS. Women and suicidal behavior: a cultural analysis. Am. J. Orthopsychiatry 78, 259-266 (2008).
90. Liu KY, Chen EY, Cheung AS, Yip PS. Psychiatric history modifes the gender ratio of suicide: an East and West comparison. Soc. Psychiatry Psychiatr. Epidemiol. 44, 130-134 (2009).
91. Yip PS, Callanan C, Yuen HP. Urban/rural and gender differentials in suicide rates: east and west. J. Affect. Disord. 57, 99-106 (2000).
92. von Borczyskowski A, Lindblad F, Vinnerljung B, Hjern A. Gender differences in risk factors for suicide: fndings from a Swedish national cohort study. Can. J. Psychiatry 55(2), 108-111 (2009).
93. Karvonen K, Sammela HL, Rahikkala H et al. Sex, timing, and depression among suicide victims with schizophrenia. Compr. Psychiatry 48, 319-322 (2007).
94. Salokangas RK. Prognostic implications of the sex of schizophrenic patients. Br. J. Psychiatry 142, 145-151 (1983).
95. Seeman MV. Suicide among women with schizophrenia spectrum disorders. J. Psychiatr. Pract. 15, 235-242 (2009).
96. Goodwin R, Lyons JS, McNally RJ. Panic attacks in schizophrenia. Schizophr. Res. 58, 213-220 (2002).
97. Hu WH, Sun CM, Lee CT, Peng SL, Lin SK, Shen WW. A clinical study of schizophrenic suicides. 42 cases in Taiwan. Schizophr. Res. 5, 43-50 (1991).
98. Baca-Garcia E, Perez-Rodriguez MM, Diaz Sastre C, Saiz-Ruiz J, de Leon J. Suicidal behavior in schizophrenia and depression: a comparison. Schizophr. Res. 75, 77-81 (2005).
99. Mann JJ, Currier D, Stanley B, Oquendo MA, Amsel LV, Ellis SP. Can biological tests assist prediction of suicide in mood disorders? Int. J. Neuropsychopharmacol. 9, 465-474 (2006).
100. Nordström P, Samuelsson M, Åsberg M et al. CSF 5-HIAA predicts suicide risk after attempted suicide. Suicide Life Threat. Behav. 24, 1-9 (1994).
101. Åsberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fuid studies. Ann. NY Acad. Sci. 836, 158-181 (1997).
102. Lester D. The concentration of neurotransmitter metabolites in the cerebrospinal fuid of suicidal individuals: a meta-analysis. Pharmacopsychiatry 28, 45-50 (1995).
103. Engström G, Alling C, Blennow K, Regnell G, Träskman-Bendz L. Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur. Neuropsychopharmacol. 9, 399-405 (1999).
104. Jokinen J, Nordström AL, Nordström P. The relationship between CSF HVA/5-HIAA ratio and suicide intent in suicide attempters. Arch. Suicide Res. 11, 187-192 (2007).
105. Roy A, Ågren H, Pickar D et al. Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindoleacetic acid ratios in depressed patients: relationship to suicidal behavior and dexamethasone nonsuppression. Am. J. Psychiatry 143, 1539-1545 (1986).
106. Mann JJ, Malone KM, Psych MR et al. Attempted suicide characteristics and cerebrospinal fuid amine metabolites in depressed inpatients. Neuropsychopharmacology 15, 576-586 (1996).
107. Träskman-Bendz L, Alling C, Oreland L, Regnell G, Vinge E, Öhman R. Prediction of suicidal behavior from biologic tests. J. Clin. Psychopharmacol. 12, S21-S26 (1992).
108. Placidi GP, Oquendo MA, Malone KM, Huang YY, Ellis SP, Mann JJ. Aggressivity, suicide attempts, and depression: relationship to cerebrospinal fuid monoamine metabolite levels. Biol. Psychiatry 50, 783-791 (2001).
109. Carlborg A, Jokinen J, Nordström AL, Jönsson EG, Nordström P. CSF 5-HIAA, attempted suicide and suicide risk in schizophrenia spectrum psychosis. Schizophr. Res. 112, 80-85 (2009).
110. Marcinko D, Pivac N, Martinac M, Jakovljevic M, Mihaljevic-Peles A, Muck-Seler D. Platelet serotonin and serum cholesterol concentrations in suicidal and non-suicidal male patients with a frst episode of psychosis. Psychiatry Res. 150, 105-108 (2007).
111. Jokinen J, Carlborg A, Mårtensson B, Forslund K, Nordström AL, Nordström P. DST non-suppression predicts suicide after attempted suicide. Psychiatry Res. 150, 297-303 (2007).
112. Plocka-Lewandowska M, Araszkiewicz A, Rybakowski JK. Dexamethasone suppression test and suicide attempts in schizophrenic patients. Eur. Psychiatry 16, 428-431 (2001).
113. Lewis CF, Tandon R, Shipley JE et al. Biological predictors of suicidality in schizophrenia. Acta Psychiatr. Scand. 94, 416-420 (1996).
114. Pickar D, Roy A, Breier A et al. Suicide and aggression in schizophrenia. Neurobiologic correlates. Ann. NY Acad. Sci. 487, 189-196 (1986).
115. Baldessarini RJ, Hennen J. Genetics of suicide: an overview. Harv. Rev. Psychiatry 12, 1-13 (2004).
116. Courtet P, Jollant F, Castelnau D, Buresi C, Malafosse A. Suicidal behavior: relationship between phenotype and serotonergic genotype. Am. J. Med. Genet. C Semin. Med. Genet. 133C, 25-33 (2005).
117. Qin P, Agerbo E, Mortensen PB. Suicide risk in relation to family history of completed suicide and psychiatric disorders: a nested case-control study based on longitudinal registers. Lancet 360, 1126-1130 (2002).
118. Runeson B, Åsberg M. Family history of suicide among suicide victims. Am. J. Psychiatry 160, 1525-1526 (2003).
119. Li D, He L. Meta-analysis supports association between serotonin transporter (5-HTT) and suicidal behavior. Mol. Psychiatry 12, 47-54 (2007).
120. 2A) gene with schizophrenia and suicidal behavior using systematic meta-analysis. Biochem. Biophys. Res. Commun. 340, 1006-1015 (2006).
121. Saetre P, Lundmark P, Wang A et al. The tryptophan hydroxylase 1 (TPH1) gene, schizophrenia susceptibility, and suicidal behavior: A multi-centre case-control study and meta-analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 387-396 (2010).
122. Fanous AH, Chen X, Wang X et al. Genetic variation in the serotonin 2A receptor and suicidal ideation in a sample of 270 Irish high-density schizophrenia families. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B, 411-417 (2009).
123. De Luca V, Tharmalingam S, Zai C et al. Association of HPA axis genes with suicidal behaviour in schizophrenia. J. Psychopharmacol. 24(5), 677-682 (2010).
124. Feldcamp LA, Souza RP, Romano-Silva M, Kennedy JL, Wong AH. Reduced prefrontal cortex DARPP-32 mRNA in completed suicide victims with schizophrenia. Schizophr. Res. 103, 192-200 (2008).
125. Wasserman D, Terenius L, Wasserman J, Sokolowski M. The 2009 Nobel conference on the role of genetics in promoting suicide prevention and the mental health of the population. Mol. Psychiatry 15, 12-17 (2010).
126. Aguilar EJ, Garcia-Marti G, Marti-Bonmati L et al. Left orbitofrontal and superior temporal gyrus structural changes associated to suicidal behavior in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1673-1676 (2008).
127. Rusch N, Spoletini I, Wilke M et al. Inferior frontal white matter volume and suicidality in schizophrenia. Psychiatry Res. 164, 206-214 (2008).
128. Maris RW, Berman A, Silverman MM. Treatment and prevention of suicide. In: Comprehensive Textbook of Suicidology. Maris RW, Berman A, Silverman MM (Eds). Guilford Press, NY, USA (2000).
129. Nordentoft M. Prevention of suicide and attempted suicide in Denmark. Epidemiological studies of suicide and intervention studies in selected risk groups. Dan. Med. Bull. 54, 306-369 (2007).
130. Mann JJ, Apter A, Bertolote J et al. Suicide prevention strategies: a systematic review. JAMA 294, 2064-2074 (2005).
131. Melle I, Johannesen JO, Friis S et al. Early detection of the frst episode of schizophrenia and suicidal behavior. Am. J. Psychiatry 163, 800-804 (2006).
132. Tiihonen J, Lönnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374, 620-627 (2009).
133. Altamura AC, Anand R, Bertoldi A et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60, 82-91 (2003).
134. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr. Res. 73, 139-145 (2005).
135. De Hert M, Correll CU, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study. Schizophr. Res. 117, 68-74 (2010).
136. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am. J. Psychiatry 162, 1805-1819 (2005).
137. Leucht S, McGrath J, Kissling W. Lithium for schizophrenia. Cochrane Database Syst. Rev. 3, CD003834 (2003).
138. Sharma V. The effect of electroconvulsive therapy on suicide risk in patients with mood disorders. Can. J. Psychiatry 46, 704-709 (2001).
139. Prudic J, Sackeim HA. Electroconvulsive therapy and suicide risk. J. Clin. Psychiatry 60(Suppl. 2), 104-110; discussion 111-1106 (1999).
140. Popeo DM. Electroconvulsive therapy for depressive episodes: a brief review. Geriatrics 64, 9-12 (2009).
141. Henriksson S, Isacsson G. Increased antidepressant use and fewer suicides in Jämtland county, Sweden, after a primary care educational programme on the treatment of depression. Acta Psychiatr. Scand. 114, 159-167 (2006).
142. Isacsson G, Rich CL. Antidepressant drug use and suicide prevention. Int. Rev. Psychiatry 17, 153-162 (2005).
143. Alaräisänen A, Heikkinen J, Kianickova Z, Miettunen J, Räsänen P, Isohanni M. Pathways leading to suicide in schizophrenia. Curr. Psych. Rev. 3, 233-242 (2007).
144. Meltzer H, Conley R, De Leo D et al. Intervention strategies for suicidality. J. Clin. Psychiatry Audiograph Series 6, 1-18 (2003).
145. Bateman K, Hansen L, Turkington D, Kingdon D. Cognitive behavioral therapy reduces suicidal ideation in schizophrenia: results from a randomized controlled trial. Suicide Life Threat. Behav. 37, 284-290 (2007).
146. Rossau CD, Mortensen PB. Risk factors for suicide in patients with schizophrenia: nested case-control study. Br. J. Psychiatry 171, 355-359 (1997).
147. De Leo D, Spathonis K. Do psychosocial and pharmacological interventions reduce sucide in schizophrenia and schizophrenia spectrum disorders? Arch. Suicide Res. 7(4), 353-374 (2003).
148. Acosta FJ, Aguilar EJ, Cejas MR, Gracia R, Caballero-Hidalgo A, Siris SG. Are there subtypes of suicidal schizophrenia? A prospective study. Schizophr. Res. 86, 215-220 (2006).
149. Skegg K. Self-harm. Lancet 366, 1471-1483 (2005).